Answers are grounded in this paper and cite their sources.
Oral 5-aminosalicylic acid (5-ASA; also known as mesalazine or mesalamine) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. In an earlier version of this review, we found that 5-ASA drugs were more effective than placebo for maintenance of remission of ulcerative colitis (UC), but had a significant therapeutic inferiority relative to SASP. In this version, we have rerun the search to bring the review up to date.
No takes yet. Share an insight, caveat, or question.
Murray et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: